PALB2 and breast cancer: The first survey of hereditary BC in Trinidad and Tobago reported 28 of 268 (10.4%) mutation-positive invasive ductal carcinoma patients as follows: 15 (53.6%) BRCA1 mutations, 10 (35.7%) BRCA2 mutations, two (7.1%) PALB2 mutations, and one case with both BRCA2 and PALB2 mutations; overall, there were 29 mutations, four of which were seen twice in unrelated patients [64].